IDSA 2026 guidelines: Practical Approach to ESBL, CRE, DTR Pseudomonas & CRAB | Antibiotic Update

Antimicrobial resistance is changing rapidly — and choosing the right antibiotic is no longer as simple as looking at the susceptibility report. In this video, we discuss the 2026 IDSA guidance for antimicrobial-resistant Gram-negative infections and translate the recommendations into practical clinical decision-making. We cover: 🔹 ESBL-producing Enterobacterales 🔹 ESBL-associated uncomplicated and complicated UTI 🔹 ESBL pneumonia, bacteremia and other invasive infections 🔹 Why piperacillin–tazobactam and cefepime require caution in ESBL infections 🔹 Carbapenem-resistant Enterobacterales (CRE) 🔹 Understanding KPC vs NDM/MBL resistance mechanisms 🔹 Newer β-lactam/β-lactamase inhibitor combinations 🔹 Difficult-to-treat resistant (DTR) Pseudomonas aeruginosa 🔹 Carbapenem-resistant Acinetobacter baumannii (CRAB) 🔹 Stenotrophomonas maltophilia 🔹 The importance of organism, resistance mechanism, infection site, AST and clinical status when selecting therapy The key message is simple: Don't just ask, "Which antibiotic is susceptible?" Ask, "What is the resistance mechanism, where is the infection, and which antibiotic is most appropriate for this patient?" This video is intended for healthcare professionals, physicians, pulmonologists, intensivists, infectious disease specialists, microbiologists, pharmacists, residents and medical students interested in antimicrobial resistance and evidence-based antibiotic therapy. 📌 Disclaimer: This video is intended for medical education and discussion. It does not replace individual patient assessment, local antimicrobial susceptibility data, institutional protocols, or specialist consultation. Subscribe to Breathackers for more clinically focused updates in respiratory medicine, infectious diseases, antimicrobial resistance and evidence-based practice. #IDSA2026 #AntimicrobialResistance #AntibioticStewardship #ESBL #CRE #Pseudomonas #CRAB #InfectiousDisease #Antibiotics #Breathackers